Ocugen, Inc.

NasdaqCM:OCGN Stock Report

Market Cap: US$427.9m

Ocugen Management

Management criteria checks 3/4

Ocugen's CEO is Shankar Musunuri, appointed in Sep 2013, has a tenure of 12.25 years. total yearly compensation is $1.94M, comprised of 39% salary and 61% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth $3.41M. The average tenure of the management team and the board of directors is 1.8 years and 5 years respectively.

Key information

Shankar Musunuri

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage39.04%
CEO tenure12.3yrs
CEO ownership0.8%
Management average tenure1.8yrs
Board average tenure5yrs

Recent management updates

Recent updates

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18
User avatar

Gene Therapy Advances Will Unlock New Treatment Options

Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.

CEO Compensation Analysis

How has Shankar Musunuri's remuneration changed compared to Ocugen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$64m

Jun 30 2025n/an/a

-US$57m

Mar 31 2025n/an/a

-US$58m

Dec 31 2024US$2mUS$758k

-US$54m

Sep 30 2024n/an/a

-US$51m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$5mUS$758k

-US$63m

Sep 30 2023n/an/a

-US$79m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$86m

Dec 31 2022US$8mUS$715k

-US$87m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$8mUS$541k

-US$58m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$2mUS$500k

-US$34m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$572kUS$420k

-US$20m

Compensation vs Market: Shankar's total compensation ($USD1.94M) is about average for companies of similar size in the US market ($USD2.31M).

Compensation vs Earnings: Shankar's compensation has been consistent with company performance over the past year.

CEO

Shankar Musunuri (61 yo)

12.3yrs
Tenure
US$1,941,539
Compensation

Dr. Shankar Musunuri, Ph D., MBA, is Co-Founder of OrthoCellix, Inc. and serves as its Chairman, Chief Executive Officer President and Secretary. Dr. Musunuri is the Co-Founder of Ocugen, Inc. since Septem...

Leadership Team

NamePositionTenureCompensationOwnership
Shankar Musunuri
Co-Founder12.3yrsUS$1.94m0.80%
$ 3.4m
Uday Kompella
Co-founder & Independent Director12.3yrsUS$101.64k0.23%
$ 966.0k
Arun Upadhyay
Chief Scientific Officer and Head of Research & Development3.3yrsUS$870.87k0.069%
$ 293.9k
Huma Qamar
Chief Medical Officer1.8yrsUS$1.73m0.0014%
$ 6.1k
Ramesh Ramachandran
Chief Accounting Officer1.2yrsno data0.00058%
$ 2.5k
John Kouch
General Counselno datano datano data
Tiffany Hamilton
AVP & Head of Corporate Communicationsno datano datano data
Kristen Craft
Head of People & Culture1.7yrsno datano data
Vijay Tammara
Chief Development Officerless than a yearUS$1.31mno data
Jyothy Pillai
VP & Head of Regulatory & Quality2.8yrsno datano data
Durgaprasad Annavajjula
VP, Head of Program Management & Chief of Staff1.9yrsno datano data
Abhi Gupta
Executive Vice President of Commercial and Business Developmentless than a yearno datano data
1.8yrs
Average Tenure
57.5yo
Average Age

Experienced Management: OCGN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Shankar Musunuri
Co-Founder6.3yrsUS$1.94m0.80%
$ 3.4m
Uday Kompella
Co-founder & Independent Director6.3yrsUS$101.64k0.23%
$ 966.0k
Carl Regillo
Member of Retina Scientific Advisory Board6.1yrsno datano data
David Boyer
Member of Retina Scientific Advisory Boardno datano datano data
Harvey Rubin
Vaccine Scientific Advisory Board Member5yrsno datano data
Catherine Pachuk
Vaccine Scientific Advisory Board Member5yrsno datano data
Bruce Forrest
Vaccine Scientific Advisory Board Member5yrsno datano data
Junge Zhang
Independent Director6.3yrsUS$86.64k0.37%
$ 1.6m
Kirsten Castillo
Independent Director5.7yrsUS$114.76k0.024%
$ 102.7k
Satishchandran Chandrasekhar
Vaccine Scientific Advisory Board Member & Independent Director5yrsno datano data
David Fajgenbaum
Vaccine Scientific Advisory Board Member5yrsno datano data
Lejla Vajzovic
Chair of Retina Scientific Advisory Board1.6yrsno datano data
5.0yrs
Average Tenure
61yo
Average Age

Experienced Board: OCGN's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/31 14:35
End of Day Share Price 2025/12/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ocugen, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniil GataulinChardan Capital Markets, LLC
Swayampakula RamakanthH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets